L
Linda Ross
Researcher at Harvard University
Publications - 19
Citations - 815
Linda Ross is an academic researcher from Harvard University. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 9, co-authored 16 publications receiving 604 citations. Previous affiliations of Linda Ross include Boston Children's Hospital & Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Proteomic and Genetic Approaches Identify Syk as an AML Target
Cynthia K. Hahn,Jacob E. Berchuck,Kenneth N. Ross,Rose M. Kakoza,Karl R. Clauser,Anna C. Schinzel,Anna C. Schinzel,Linda Ross,Ilene Galinsky,Tina N. Davis,Serena J. Silver,David E. Root,Richard Stone,Daniel J. DeAngelo,Martin Carroll,William C. Hahn,William C. Hahn,Steven A. Carr,Todd R. Golub,Todd R. Golub,Todd R. Golub,Andrew L. Kung,Kimberly Stegmaier,Kimberly Stegmaier +23 more
TL;DR: This report integrated proteomic and RNAi-based strategies to identify their off-target, anti-AML mechanism and genetic and pharmacological inactivation of Syk with a drug in clinical trial for other indications promoted differentiation of AML cells and attenuated leukemia growth in vivo.
Journal ArticleDOI
Targeting MTHFD2 in acute myeloid leukemia
Yana Pikman,Yana Pikman,Alexandre Puissant,Alexandre Puissant,Alexandre Puissant,Gabriela Alexe,Andrew Furman,Andrew Furman,Liying M. Chen,Liying M. Chen,Stacey M. Frumm,Stacey M. Frumm,Linda Ross,Linda Ross,Nina Fenouille,Christopher F. Bassil,Christopher F. Bassil,Caroline A. Lewis,Azucena Ramos,Joshua Gould,Richard Stone,Daniel J. DeAngelo,Ilene Galinsky,Clary B. Clish,Andrew L. Kung,Michael T. Hemann,Matthew G. Vander Heiden,Matthew G. Vander Heiden,Versha Banerji,Versha Banerji,Versha Banerji,Kimberly Stegmaier,Kimberly Stegmaier,Kimberly Stegmaier +33 more
TL;DR: Pikman et al. demonstrate that the mitochondrial enzyme MTHFD2 is a potential therapeutic target in acute myeloid leukemia and it is shown that the enzyme could be a new therapeutic target for these patients.
Journal ArticleDOI
CRISPR-Cas9 screen reveals a MYCN -amplified neuroblastoma dependency on EZH2
Liying Chen,Liying Chen,Gabriela Alexe,Neekesh V. Dharia,Neekesh V. Dharia,Linda Ross,Amanda Balboni Iniguez,Amanda Balboni Iniguez,Amy Saur Conway,Emily Jue Wang,Veronica Veschi,Norris Lam,Jun Qi,W. Clay Gustafson,Nicole Nasholm,Francisca Vazquez,Barbara A. Weir,Glenn S. Cowley,Levi D. Ali,Sasha Pantel,Guozhi Jiang,William F. Harrington,Yenarae Lee,Amy Goodale,Rakela Lubonja,John M. Krill-Burger,Robin M. Meyers,Aviad Tsherniak,David E. Root,James E. Bradner,James E. Bradner,Todd R. Golub,Todd R. Golub,Charles W. M. Roberts,Charles W. M. Roberts,William C. Hahn,William C. Hahn,William A. Weiss,Carol J. Thiele,Kimberly Stegmaier,Kimberly Stegmaier +40 more
TL;DR: It is demonstrated that MYCN upregulates EZH2, leading to inactivation of a tumor suppressor program in neuroblastoma, and support testing EZh2 inhibitors in patients with MYCN-amplified neuroblastomas.
Journal ArticleDOI
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia
Versha Banerji,Stacey M. Frumm,Stacey M. Frumm,Kenneth N. Ross,Kenneth N. Ross,Loretta S. Li,Loretta S. Li,Anna C. Schinzel,Anna C. Schinzel,Cynthia K. Hahn,Cynthia K. Hahn,Rose M. Kakoza,Rose M. Kakoza,Kwan T. Chow,Kwan T. Chow,Linda Ross,Linda Ross,Gabriela Alexe,Gabriela Alexe,Nicola Tolliday,Nicola Tolliday,Haig Inguilizian,Haig Inguilizian,Ilene Galinsky,Richard Stone,Daniel J. DeAngelo,Giovanni Roti,Giovanni Roti,Jon C. Aster,William C. Hahn,Andrew L. Kung,Andrew L. Kung,Kimberly Stegmaier +32 more
TL;DR: A role for glycogen synthase kinase 3α (GSK-3α) in acute leukemia is identified by performing 2 independent small-molecule library screens and an shRNA screen for perturbations that induced a differentiation expression signature in AML cells.
Journal ArticleDOI
Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Florence F. Wagner,Lina Benajiba,Arthur Campbell,Michel Weiwer,Joshua R. Sacher,Jennifer Gale,Linda Ross,Linda Ross,Alexandre Puissant,Alexandre Puissant,Alexandre Puissant,Gabriela Alexe,Amy Saur Conway,Amy Saur Conway,Morgan Back,Morgan Back,Yana Pikman,Yana Pikman,Yana Pikman,Ilene Galinsky,Daniel J. DeAngelo,Richard Stone,Taner Kaya,Xi Shi,Matthew B. Robers,Thomas Machleidt,Jennifer Wilkinson,Olivier Hermine,Olivier Hermine,Andrew L. Kung,Adam J. Stein,Damodharan Lakshminarasimhan,Michael T. Hemann,Edward M. Scolnick,Yan-Ling Zhang,Jen Q. Pan,Kimberly Stegmaier,Kimberly Stegmaier,Kimberly Stegmaier,Edward Holson +39 more
TL;DR: It is shown that selective GSK3α inhibitors specifically show promising activity against acute myeloid leukemia with no detectable effects on healthy hematopoietic cells, and a rational design strategy toward the discovery of paralog-selective G SK3 inhibitors is presented.